ESMO 2018 | Adverse events in bladder cancer immunotherapy
Jonathan Rosenberg
• 18 Jan 2019
Jonathan Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY, talks about immune-related adverse events from bladder cancer immunotherapy, at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Dr Rosenberg suggests that there is higher tolerability for ipilimumab in patients; however, certain patient populations exhibit irreversible long-term side effects, such as adrenal or pituitary dysfunction. Nevertheless, there appear to be many novel agents showing promise in the field of urothelial cancer treatment.
